CONTEXT: Commercial merger announcement. Advise caution with regards to applicability in RWR as the technology platform is heavily clinical research focused. IMPACT: Low READ TIME: 1 min *1. “MUNICH–(BUSINESS WIRE)–XClinical, Continue Reading
CONTEXT: Commercial announcement mirroring the developing trend in pulling together RWE data sources and analytical capabilities in response to the regulatory need for more granularity to assess the safety, health, Continue Reading
CONTEXT: FDA publishing an action plan on AI in SAAMDs. China already ahead of the game in terms of how they have already enacted guidance on AI in SAAMDs, but Continue Reading
CONTEXT: Mostly advert for cox platform, but interesting EMR based use of RWD – stretching the definition of a decentralised study though, US Only IMPACT: RWE insights based on de-identified Continue Reading
CONTEXT: BMJ article describing a framework for RWE study design toencourage reproducibility. The framework is intended for use in studieslooking at effectiveness and safety of medical products and claims to Continue Reading
CONTEXT: Oncology news article on use of RWR in oncology. Nothing new in terms of data use, more confirmation of RWD in oncology research. However, an interesting perspective from the Continue Reading
CONEXT: Denmark | De-Centralised Trials | Regulatory Update | RWR and Regulators | RWR IMPACT: Regulator endorsed initiative for de-centralised trials|Making clinical research results more ‘real’ READ TIME: 2.5 mins Continue Reading
CONTEXT: RWR & Regulators | Regulatory Updates | RWR | Ireland | Retrospective Chart Reviews IMPACT: High = New regulatory framework to support (improve?) the conduct of retrospective chart reviews Continue Reading
There is no excerpt because this is a protected post.
There is no excerpt because this is a protected post.
